Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab in pediatric patients with AQP4+ NMOSD
NCT05199688Phase 3Recruiting
- Sponsor
- Roche
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, open-label trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (3 cohorts), sponsored by Roche. Primary endpoints: Observed Serum Concentration of Satralizumab at 48 weeks, Apparent Clearance of Satralizumab at 48 weeks and 2 more. Started May 2026; status: recruiting.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05199688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199688.